Jackson A, Tattersall D, Bentley G, Rycroft W, Bourson A, Hargreaves R, Tricklebank M, Iversen S
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
Neuropeptides. 1994 May;26(5):343-53. doi: 10.1016/0143-4179(94)90119-8.
The discriminative stimulus properties of the selective CCKB-receptor antagonist, L-365,260 were evaluated in rats trained to discriminate diazepam (2 mg/kg) or morphine (5 mg/kg) from vehicle, using a two-lever food reinforced technique. In the diazepam drug discrimination, the benzodiazepine-receptor agonist FG8205 (0.063-2 mg/kg) produced dose-related drug associated responding, whereas L-365,260 (0.125-4 mg/kg) treated animals showed vehicle appropriate behaviour. In rats trained to discriminate morphine from saline, L-365,260 (0.063-4 mg/kg) produced saline lever responding. When a dose of 1 mg/kg L-365,260 was administered in combination with morphine, the dose response curve for drug lever responding was not significantly affected. This was in contrast to the effect produced by the opiate antagonist naloxone (0.3 mg/kg) which shifted the dose-response curve to the right. Another group of rats underwent training to discriminate a dose of 6 mg/kg L-365,260 from vehicle. None of the animals learned the discrimination within 50 daily training sessions. In addition, unlike morphine (3 mg/kg), or changing the training dose of cocaine, intravenous administration of L-365,260 (0.3-10 mg/kg) did not modify lever pressing or the number of injections received by rats trained to self administer cocaine (0.25 mg/injection). L-365,260 (0.1-3 mg/kg) produced a dose-related inhibition of pentagastrin-stimulated gastric acid secretion in vivo. When administered dissolved in a mixture of ethanol/propylene glycol/saline, the ID50 was 0.83 mg/kg, and when suspended in an ethanol/carboxymethylcellulose vehicle, it was 0.7 mg/kg. It was concluded: 1) that L-365,260 does not produce discriminative stimuli similar to either diazepam or morphine; 2) that the potentiation of morphine-induced behaviour by L-365,260 does not extend to the discriminative stimulus properties of morphine; 3) that L-365,260 itself does not produce readily discriminable interoceptive stimuli in rats; and 4) that L-365,260 does not substitute for the reinforcing drug cocaine.
采用双杠杆食物强化技术,在训练大鼠区分地西泮(2毫克/千克)或吗啡(5毫克/千克)与溶剂的实验中,评估了选择性CCKB受体拮抗剂L-365,260的辨别刺激特性。在地西泮药物辨别实验中,苯二氮䓬受体激动剂FG8205(0.063 - 2毫克/千克)产生了与剂量相关的药物关联反应,而接受L-365,260(0.125 - 4毫克/千克)处理的动物表现出与溶剂相符的行为。在训练大鼠区分吗啡与生理盐水的实验中,L-365,260(0.063 - 4毫克/千克)使大鼠产生了选择生理盐水杠杆的反应。当将1毫克/千克的L-365,260与吗啡联合给药时,药物杠杆反应的剂量 - 反应曲线未受到显著影响。这与阿片类拮抗剂纳洛酮(0.3毫克/千克)产生的效应形成对比,纳洛酮使剂量 - 反应曲线右移。另一组大鼠接受训练以区分6毫克/千克的L-365,260与溶剂。在50次每日训练 sessions内,没有动物学会这种辨别。此外,与吗啡(3毫克/千克)不同,也与改变可卡因的训练剂量不同,静脉注射L-365,260(0.3 - 10毫克/千克)并未改变训练自行注射可卡因(0.25毫克/注射)的大鼠的杠杆按压行为或注射次数。L-365,260(0.1 - 3毫克/千克)在体内对五肽胃泌素刺激的胃酸分泌产生了与剂量相关的抑制作用。当溶解于乙醇/丙二醇/生理盐水的混合物中给药时,半数抑制剂量(ID50)为0.83毫克/千克,当悬浮于乙醇/羧甲基纤维素溶剂中给药时,ID50为0.7毫克/千克。得出以下结论:1)L-365,260不会产生与地西泮或吗啡相似的辨别刺激;2)L-365,260对吗啡诱导行为的增强作用并不扩展至吗啡的辨别刺激特性;3)L-365,260本身在大鼠中不会产生易于辨别的内感受性刺激;4)L-365,260不能替代强化药物可卡因。 (注:“sessions”可能是“实验时段”之类的意思,这里保留英文未翻译准确,因为原文可能有特定专业含义)